1. Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes. Diabetes Ther. 2018 Feb;9(1):383-394 GLP 2. Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS). Clin Pediatr Endocrinol. 2017;26(4):229-241 3. Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial. Endocr J. 2017 Jul 28;64(7):705-717. 25 50 50 4. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocr J. 2017 May 30;64(5):553-560 GLP 5. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials. Endocr J. 2017 Feb 27;64(2):191-206. GLP 6. Caveolin-1 facilitates internalization and degradation of ABCA1 and probucol oxidative products interfere with this reaction to increase HDL biogenesis. Atherosclerosis. 2016 Oct;253:54-60.
HDL ABCA1 HDL 7. Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial. J Diabetes Investig. 2017 Jan;8(1):75-83. 25 50 50 8. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study). Diabetes Metab Res Rev. 2017 Jan;33(1). 9. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016 Mar;18(3):249-57. 10. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015 Oct;17(10):974-83. GLP HbA1c 1.4 11. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016;63(3):263-73 GLP 12. [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)]. Nihon Yakurigaku Zasshi. 2015 Oct;146(4):215-24. GLP
13. Deficiency in the Lipid Exporter ABCA1 Impairs Retrograde Sterol Movement and Disrupts Sterol Sensing at the Endoplasmic Reticulum. J Biol Chem. 2015 Sep 25;290(39):23464-77. HDL ABCA1 ABCA1 14. Possible predictors for QOL improvement following GH replacement therapy in adult GHD. Endocr J. 2015;62(8):749-56 QOL QOL QOL 15. Effect of growth hormone treatment on quality of life in Japanese children with growth hormone deficiency: an analysis from a prospective observational study. Clin Pediatr Endocrinol. 2014 Jul;23(3):83-92. (QOL) 16. Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis. Ther Apher Dial. 2014 Feb;18(1):93-102. LDL 17. Defining patients at extremely high risk for coronary artery disease in heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(4):369-75 LDL C
18. Calpain-mediated ABCA1 degradation: post-translational regulation of ABCA1 for HDL biogenesis. Biochim Biophys Acta. 2012 Mar;1821(3):547-51. ABCA1 19. HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATPbinding cassette transporter A7. Atherosclerosis. 2011 Aug;217(2):407-14. ABCA7 ABCA7 ABCA7 20. Protein kinase D regulates the adiponectin gene expression through phosphorylation of AP-2: a common pathway to the ABCA1 gene regulation. Atherosclerosis. 2011 May;216(1):90-6. ABCA1 AP2 26 21. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb. 2011;18(4):274-81 ABCA7 22. Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J Lipid Res. 2010 Sep;51(9):2591-9. HDL C ABCA7 23. Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1446-52. ABCA1 HDL 24. Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis. J Lipid Res. 2009 Nov;50(11):2299-305.
HDL 2018 25. FGF-1 induces expression of LXRalpha and production of 25-hydroxycholesterol to upregulate the apoe gene in rat astrocytes. J Lipid Res. 2009 Jun;50(6):1156-64. FGF HDL E 26. Involvement of protein kinase D in phosphorylation and increase of DNA binding of activator protein 2 alpha to downregulate ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2282-7. AP2 PKD DNA ABCA1 30 27. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1820-4. HDL C A-I ABCA1 ABCA1 28. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J Lipid Res. 2008 Feb;49(2):386-93. SAA ABCA1 HDL 29. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. J Atheroscler Thromb. 2007 Jun;14(3):133-41. ARB PPARγ ABCA1 30. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Circ Res. 2007 Jul 20;101(2):156-65. α
31. ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis. J Lipid Res. 2006 Sep;47(9):1915-27. ABCA7 ABCA7 ABCA7 32. Serum amyloid A generates high density lipoprotein with cellular lipid in an ABCA1- or ABCA7-dependent manner. J Lipid Res. 2006 Jul;47(7):1542-50 SAA ABCA1 ABCA7 HDL 33. Glucocorticoid receptor regulates ATP-binding cassette transporter-a1 expression and apolipoprotein-mediated cholesterol efflux from macrophages. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):163-8. 34. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol. 2005 Mar 1;45(5):733-42. MRI 35. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb. 2005;12(1):53-60. TLR2 TLR 36. Gln27Glu beta2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Clin Chim Acta. 2001 Dec;314(1-2):85-91. β
β 1. 1 Progress in Medicine(0287-3648)38 3 Page293-300(2018.03) 2. 1 GLP-1 1 Progress in Medicine(0287-3648)36 11 Page1571-1577(2016.11) 3. GLP-1 ( ) ( 0.75mg ) (1341-8815)51 12 Page1477-1479(2015.12) 4. 1 GLP-1 ( ) (0015-5691)146 4 Page215-224(2015.10) 5. ( ) growth hormone Humatrope (0385-6305)45 10 Page1901-1908(2013.10) 6. 1 Progress in Medicine(0287-3648)32 8 Page1743-1748(2012.08) 7. Update- (0910-5808)27 12 Page1555-1560(2011.11) 8. FH 4 Progress in Medicine(0287-3648)31 12 Page2894-2900(2011.12) 9. PKD/AP-2 ABCA1 adiponectin (0285-1520)53 Page216-219(2011.04) 10. (ASO) ASO LDL (0022-5207)93 4 Page655-660(2011.04) 11. ASO! (0022-5207)93 4 Page619-622(2011.04) 12.
(0044-0035)62 5 Page2422-2429(2011.04) 13. LDL (0385-9215)4520 Page75-74(2010.12) 14. ( 16 ) Life Style Medicine(1881-5421)4 4 Page361-367(2010.10) 15. PCSK9 ARH Medical Technology(0389-1887)38 10 Page975-976(2010.10) 16. HDL ABCA1 Vascular Medicine(1880-2478)5 2 Page117-126(2009.04) 17. Update 2007 ABCA Therapeutic Research(0289-8020)29 2 Page175(2008.02) 18. (0452-3458)52 1 Page13-21(2004.01) 19. E (Effects of Soy Protein on Levels of Remnant-like Particles Cholesterol and Vitamin E in Healthy Men)( ) Journal of Nutritional Science and Vitaminology(0301-4800)47 4 Page283-288(2001.08) 20. C-I (0047-1852)59 2 ( ) Page114-119(2001.02) 21. LDL Progress in Medicine(0287-3648)19 5 Page1252-1255(1999.05) 22. (0386-7722)25 6 Page895-897(1999.05) 1. 2 III β 2017 2. ABC ABCA1 2015
3. 2 25 50 2016 4. 1 0.75mg? 2016 5. 2 0.75mg III 2016 6. 2 0.75mg 2016 7. 2 0.75mg ( ) 2016 8. 2 25 50 2015 9. 2 1 dulaglutide 2015 10. Dulaglutide 2 2015 11. 1 GLP-1 1 2015 12. GHD GH QOL 2014 13. FH LDL-A 2011 14. LDL-Apheresis 2011 15. LDL FH LDL 2011 16. FH PCSK
2011 17. 2011 18. 2011 19. 2 2012 20. 2 2012 21. 2 2012 22. 2012 23. HMG-CoA ABCA7 2010 24. 2 2011 25. LDLR PCSK9 LDL-C 2011 26. LDLR PCSK9 LDL-C 2011 27. 2 CD34+ 2011 28. 2 2011 29. DPP4 2011 30. 3 2 2010
31. HDL apoa-i ABCA7 2009 32. Protein Kinase D AP2 ABCA1 ( ) 2008 33. SAA ABCA1 2007 34. FGF-1 apoe-hdl LXR ( ) 2007 35. SAA ABCA1 ( ) 2007 36. HDL ABCA1 HDL 2007 37. SAA-HDL ABCA1 2006 38. ATP A7 SREBP2 2006 39. SAA HDL 2005 40. LDL 2005 41. ABCA1KO ABCA7 2005 42. Serum amyloid A 2005 43. ABCA1 KO ABCA7 2005 44. Serum amyloid A HDL 2005 45. ABCA1KO ABCA7
2005 46. (SERM) 2003 47. Malondialdehyde-modified LDL(MDA-LDL) 2003 48. ABCA1 2003 49. T 1 2004 50. CRP 2002 51. THP-1 macrophage ABCA1 2002 52. 1 2003 53. 5 1 2002 54. PCPS 1 2002 55. β2 (codon27), 2002 56. VEGF 2001 57. 2000 58. 1999
59. LDL 1999 60. 1999